Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts’ projections, driven by ...

The Astellas Pharma executive was sentenced to 3½ years in a case that has added strain to relations between Tokyo and Beijing.

KISED will oversee management and provide research funding for the programme. Astellas will offer selected Korean ...

A Chinese court said he had been paid to provide information on China's politics and economy to intelligence agencies.

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

A Beijing district court that imposed the prison sentence is believed to have found the man guilty of espionage for providing ...

Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) agreed to buy Propella Therapeutics Inc. for about US$175 million. Propella is a privately held biopharmaceutical company that has leveraged a ...

Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy). Within the past quarter, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 15.3% higher.

Astellas Pharma Inc., based in Tokyo, announced July 11 that it completed its previously announced $5.9 billion acquisition of Iveric Bio Inc., an early-stage biopharmaceutical company based in ...

Astellas hires first chief patient exec to make 'centricity' more than a buzzword By Beth Snyder Bulik Sep 6, 2019 6:19pm C-suite management changes patient-centricity pharma hiring ...

The Astellas study has again been placed under clinical hold, a regulatory action the FDA took after the company’s Sept. 1 disclosure of abnormal liver function in the patient.